On this page
L’Oréal India wins CCI approval to acquire Innovist parent Onesto Labs
Our read
L’Oréal will use Innovist as its India digital-first growth engine, rapidly pushing Bare Anatomy and Chemist at Play into omnichannel distribution while preserving their founder-led, science-forward positioning.
For operators
L’Oréal India’s acquisition of Onesto Labs adds high-growth digital-native brands Bare Anatomy and Chemist at Play to its Consumer Products Division, expanding its omnichannel reach in India’s personal-care market.
Watch
Transaction closing announcement and disclosed purchase consideration or valuation indicators.
The report,
CCI approved L’Oréal India’s acquisition of 100% of Onesto Labs, the Innovist parent of Bare Anatomy and Chemist at Play. Innovist’s founders will continue operating the digital-first, omnichannel personal-care business under L’Oréal’s Consumer Products Division.
- Onesto Labs shareholding to be acquired by L'Oréal India
- 100%
Reported figures
From the report. Source details below
| Onesto Labs rebranded as Innovist in | 2022 |
|---|---|
| L'Oréal has operated in India since | 1994 |
Also in the report
- 26 brands in L'Oréal India's portfolio
Other figures
- 2 manufacturing units
- Innovist founded in 2019
Why it matters to operators
The transaction shows global beauty incumbents using acquisitions of founder-led, digital-native brands to gain local consumer relevance, e-commerce capabilities, and faster exposure to India’s personal-care growth.
What to watch next
- Changes in founders’ titles, reporting lines, equity incentives and senior Innovist employee retention.
- Offline distribution expansion, including placement at Nykaa, Reliance Retail, Shoppers Stop, pharmacies and general trade.
- SKU rationalization, reformulations, new clinical claims or price-pack changes after integration.
- Marketplace ranking, review volume, repeat-rate signals and promotional intensity for Bare Anatomy and Chemist at Play.
- L’Oréal India’s next earnings commentary on Consumer Products Division growth, acquisition integration and India investment.
Show 1 more
- Competitive responses from Honasa, Nykaa brands, Unilever, P&G and other science-led Indian personal-care entrants.
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- Keep Innovist founders in visible operating and brand-building roles to preserve digital-native credibility and retention.
- Expand Bare Anatomy and Chemist at Play selectively into L’Oréal’s offline distribution network, prioritizing high-velocity pharmacy, beauty-specialty and modern-trade doors.
- Use L’Oréal R&D, claims substantiation and packaging procurement to accelerate clinically positioned hair, scalp, deodorant and bodycare launches.
- Integrate marketplace data, loyalty, CRM and media-buying capabilities to reduce customer-acquisition costs and improve repeat purchase.
- Evaluate additional India D2C acquisitions or minority investments in adjacent high-growth segments such as dermocosmetics, fragrance, men’s grooming and hair/scalp treatment.
The counter-case
The case against this reading — not reported by the source.
CCI approval is procedural rather than proof of strategic success. L’Oréal may be acquiring digital-native brands at a premium just as India’s D2C beauty market becomes more crowded, customer-acquisition costs rise, and online growth normalizes. Folding founder-led brands into a multinational consumer-products division could dilute their speed, authenticity and innovation, while channel expansion risks cannibalizing L’Oréal’s existing mass-market portfolio. The lack of a disclosed closing date, valuation or financial metrics makes it impossible to assess whether the deal is material or value-accretive.
The source
First seen